{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:22:29Z","timestamp":1786990949950,"version":"build-2736575974"},"reference-count":50,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T00:00:00Z","timestamp":1684281600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81874220"],"award-info":[{"award-number":["81874220"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2019A1515011420"],"award-info":[{"award-number":["2019A1515011420"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2020A1515010030"],"award-info":[{"award-number":["2020A1515010030"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.ijrobp.2023.05.021","type":"journal-article","created":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T02:45:37Z","timestamp":1684464337000},"page":"809-820","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["A Surrogate Endpoint for Overall Survival in Locally Advanced and Resectable Esophageal Squamous Cell Carcinoma: A Reanalysis of Data From the NEOCRTEC5010 Trial"],"prefix":"10.1016","volume":"117","author":[{"given":"Tiantian","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zewei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiliang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujia","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junye","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mian","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaoqiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengzhong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1233-9189","authenticated-orcid":false,"given":"Lei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2023.05.021_bib0001","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ijrobp.2023.05.021_bib0002","doi-asserted-by":"crossref","first-page":"17048","DOI":"10.1038\/nrdp.2017.48","article-title":"Oesophageal cancer","volume":"3","author":"Smyth","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.ijrobp.2023.05.021_bib0003","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.suc.2019.02.002","article-title":"Multidisciplinary therapy of esophageal cancer","volume":"99","author":"Egyud","year":"2019","journal-title":"Surg Clin North Am"},{"key":"10.1016\/j.ijrobp.2023.05.021_bib0004","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"Al-Batran","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2023.05.021_bib0005","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/SLA.0000000000001905","article-title":"Survival after neoadjuvant and adjuvant treatments compared to surgery alone for resectable esophageal carcinoma: A network meta-analysis","volume":"265","author":"Pasquali","year":"2017","journal-title":"Ann Surg"},{"key":"10.1016\/j.ijrobp.2023.05.021_bib0006","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","article-title":"Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer","volume":"384","author":"Kelly","year":"2021","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ijrobp.2023.05.021_bib0007","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ejca.2020.11.039","article-title":"Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1)","volume":"144","author":"Li","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijrobp.2023.05.021_bib0008","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.772450","article-title":"The sequence of chemotherapy and toripalimab might influence the efficacy of neoadjuvant chemoimmunotherapy in locally advanced esophageal squamous cell cancer: A phase II study","volume":"12","author":"Xing","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.ijrobp.2023.05.021_bib0009","article-title":"Camrelizumab plus chemotherapy as neoadjuvant therapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019): A multicenter, open-label, single-arm, phase 2 study","volume":"39","author":"Li","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.05.021_bib0010","article-title":"A phase II study of neoadjuvant immunotherapy combined with chemotherapy (camrelizumab plus albumin paclitaxel and carboplatin) in resectable thoracic esophageal squamous cell cancer (NICE study): Interim results","volume":"39","author":"Li","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.05.021_bib0011","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1017\/S0266462314000300","article-title":"Validation of surrogate endpoints in advanced solid tumors: Systematic review of statistical methods, results, and implications for policy makers","volume":"30","author":"Ciani","year":"2014","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.ijrobp.2023.05.021_bib0012","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1001\/jamainternmed.2015.2829","article-title":"The strength of association between surrogate end points and survival in oncology: A systematic review of trial-level meta-analyses","volume":"175","author":"Prasad","year":"2015","journal-title":"JAMA Int Med"},{"key":"10.1016\/j.ijrobp.2023.05.021_bib0013","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ejca.2019.10.001","article-title":"Disease-free survival as a surrogate for overall survival in neoadjuvant trials of gastroesophageal adenocarcinoma: Pooled analysis of individual patient data from randomised controlled trials","volume":"123","author":"Ronellenfitsch","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijrobp.2023.05.021_bib0014","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1016\/j.ejso.2017.06.017","article-title":"Surrogacy of progression-free survival (PFS) for overall survival (OS) in esophageal cancer trials with preoperative therapy: Literature-based meta-analysis","volume":"43","author":"Kataoka","year":"2017","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ijrobp.2023.05.021_bib0015","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejca.2017.01.032","article-title":"Surrogate end-points for overall survival in 22 neoadjuvant trials of gastro-oesophageal cancers","volume":"76","author":"Petrelli","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijrobp.2023.05.021_bib0016","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S1470-2045(18)30750-2","article-title":"Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: A systematic review and meta-analysis","volume":"20","author":"Saad","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2023.05.021_bib0017","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ejca.2022.04.027","article-title":"Disease-free survival as a surrogate endpoint for overall survival in adults with resectable esophageal or gastroesophageal junction cancer: A correlation meta-analysis","volume":"170","author":"Ajani","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijrobp.2023.05.021_bib0018","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1001\/jamasurg.2021.2373","article-title":"Long-term efficacy of neoadjuvant chemoradiotherapy plus surgery for the treatment of locally advanced esophageal squamous cell carcinoma: The NEOCRTEC5010 randomized clinical trial","volume":"156","author":"Yang","year":"2021","journal-title":"JAMA Surg"},{"key":"10.1016\/j.ijrobp.2023.05.021_bib0019","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.ijrobp.2007.10.009","article-title":"Treatment outcome and recursive partitioning analysis-based prognostic factors in patients with esophageal squamous cell carcinoma receiving preoperative chemoradiotherapy","volume":"71","author":"Kim","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.05.021_bib0020","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1002\/bjs.9253","article-title":"Relevance of [18F]fluorodeoxyglucose positron emission tomography-positive lymph nodes after neoadjuvant chemotherapy for squamous cell oesophageal cancer","volume":"100","author":"Miyata","year":"2013","journal-title":"Br J Surg"},{"key":"10.1016\/j.ijrobp.2023.05.021_bib0021","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1245\/s10434-014-4195-3","article-title":"Oncologic outcomes according to remnant lymph node metastases in pathologic t0 (ypt0) esophageal squamous cell carcinoma following prospective neoadjuvant therapy and surgery","volume":"22","author":"Cho","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ijrobp.2023.05.021_bib0022","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00280-015-2806-8","article-title":"Impact of docetaxel in addition to cisplatin and fluorouracil as neoadjuvant treatment for resectable stage III or t3 esophageal cancer: A propensity score-matched analysis","volume":"76","author":"Nomura","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ijrobp.2023.05.021_bib0023","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1245\/s10434-015-4764-0","article-title":"Is there a correlation between clinical complete response and pathological complete response after neoadjuvant chemoradiotherapy for esophageal squamous cell cancer?","volume":"23","author":"Liu","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ijrobp.2023.05.021_bib0024","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1007\/s10147-016-0963-3","article-title":"Comparison between surgery and definitive chemoradiotherapy for patients with resectable esophageal squamous cell carcinoma: A propensity score analysis","volume":"21","author":"Nomura","year":"2016","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.05.021_bib0025","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1016\/j.ejso.2017.09.022","article-title":"An analysis of factors affecting the accuracy of endoscopic biopsy after neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma","volume":"43","author":"Chao","year":"2017","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ijrobp.2023.05.021_bib0026","doi-asserted-by":"crossref","first-page":"3542","DOI":"10.18632\/oncotarget.12200","article-title":"Supraclavicular and\/or celiac lymph node metastases from thoracic esophageal squamous cell carcinoma did not compromise survival following neoadjuvant chemoradiotherapy and surgery","volume":"8","author":"Cho","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ijrobp.2023.05.021_bib0027","doi-asserted-by":"crossref","first-page":"41102","DOI":"10.18632\/oncotarget.17062","article-title":"A prognostic nomogram for overall survival after neoadjuvant radiotherapy or chemoradiotherapy in thoracic esophageal squamous cell carcinoma: A retrospective analysis","volume":"8","author":"Deng","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ijrobp.2023.05.021_bib0028","first-page":"1569","article-title":"Number of resected lymph nodes and survival of patients with locally advanced esophageal squamous cell carcinoma receiving preoperative chemoradiotherapy","volume":"38","author":"Guo","year":"2018","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ijrobp.2023.05.021_bib0029","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1007\/s00268-017-4283-1","article-title":"Evaluation of prognostic factors for esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy followed by surgery","volume":"42","author":"Hamai","year":"2018","journal-title":"World J Surg"},{"key":"10.1016\/j.ijrobp.2023.05.021_bib0030","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1002\/bjs.10960","article-title":"Oesophagectomy with or without supraclavicular lymphadenectomy after neoadjuvant treatment for squamous cell carcinoma of the oesophagus","volume":"105","author":"Mine","year":"2018","journal-title":"Br J Surg"},{"key":"10.1016\/j.ijrobp.2023.05.021_bib0031","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.2147\/CMAR.S195355","article-title":"Long-term survival of patients with locally advanced esophageal squamous cell carcinoma receiving esophagectomy following neoadjuvant chemotherapy: A cohort study","volume":"11","author":"Huang","year":"2019","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.ijrobp.2023.05.021_bib0032","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s00595-018-1718-8","article-title":"Safety and efficacy of preoperative chemotherapy followed by esophagectomy versus upfront surgery for resectable esophageal squamous cell carcinoma","volume":"49","author":"Kurogochi","year":"2019","journal-title":"Surg Today"},{"key":"10.1016\/j.ijrobp.2023.05.021_bib0033","doi-asserted-by":"crossref","first-page":"e1022","DOI":"10.1097\/SLA.0000000000003727","article-title":"Prognostic impact of postoperative lymph node metastases after neoadjuvant chemoradiotherapy for locally advanced squamous cell carcinoma of esophagus: From the results of NEOCRTEC5010, a randomized multicenter study","volume":"274","author":"Leng","year":"2021","journal-title":"Ann Surg"},{"key":"10.1016\/j.ijrobp.2023.05.021_bib0034","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1245\/s10434-019-07334-7","article-title":"Treatment-related lymphopenia predicts pathologic complete response and recurrence in esophageal squamous cell carcinoma undergoing neoadjuvant chemoradiotherapy","volume":"26","author":"Li","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ijrobp.2023.05.021_bib0035","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1245\/s10434-020-09106-0","article-title":"Distribution of lymph node metastasis in esophageal squamous cell carcinoma after trimodal therapy","volume":"28","author":"Hamai","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ijrobp.2023.05.021_bib0036","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.7150\/jca.34567","article-title":"Comparison of the prognostic difference between YPTNM and equivalent PTNM stages in esophageal squamous cell carcinoma based on the 8th edition of AJCC classification","volume":"11","author":"Jiang","year":"2020","journal-title":"J Cancer"},{"key":"10.1016\/j.ijrobp.2023.05.021_bib0037","doi-asserted-by":"crossref","first-page":"5715","DOI":"10.21873\/anticanres.14586","article-title":"Prognostic significance of combined platelet distribution width and C-reactive protein score in esophageal cancer","volume":"40","author":"Kawakita","year":"2020","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ijrobp.2023.05.021_bib0038","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1245\/s10434-020-08260-9","article-title":"The prognostic impact of extracapsular lymph node involvement in esophageal squamous cell carcinoma","volume":"27","author":"Lin","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ijrobp.2023.05.021_bib0039","series-title":"AJCC Cancer Staging Manual","year":"2002"},{"key":"10.1016\/j.ijrobp.2023.05.021_bib0040","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: Reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Meth"},{"key":"10.1016\/j.ijrobp.2023.05.021_bib0041","article-title":"Updated guidance for trusted systematic reviews: A new edition of the Cochrane Handbook for Systematic Reviews of Interventions","volume":"10","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ijrobp.2023.05.021_bib0042","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1200\/JCO.2006.10.4760","article-title":"Long-term results of RTOG trial 8911 (USA intergroup 113): A random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer","volume":"25","author":"Kelsen","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.05.021_bib0043","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1200\/JCO.20.03614","article-title":"Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: The randomized controlled cross trial","volume":"39","author":"Eyck","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.05.021_bib0044","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1200\/JCO.2013.51.2186","article-title":"Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the cross trials","volume":"32","author":"Oppedijk","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.05.021_bib0045","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jtcvs.2018.09.136","article-title":"Patterns and risk of recurrence in patients with esophageal cancer with a pathologic complete response after chemoradiotherapy followed by surgery","volume":"157","author":"Barbetta","year":"2019","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.ijrobp.2023.05.021_bib0046","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1158\/1078-0432.CCR-12-1515","article-title":"Progression-free survival as a surrogate endpoint for median overall survival in metastatic colorectal cancer: Literature-based analysis from 50 randomized first-line trials","volume":"19","author":"Giessen","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2023.05.021_bib0047","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/cncr.28221","article-title":"Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma","volume":"120","author":"Halabi","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2023.05.021_bib0048","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1002\/cam4.4751","article-title":"Progression-free survival at 3 years is a reliable surrogate for 5-year overall survival for patients suffering from locally advanced esophageal squamous cell carcinoma","volume":"11","author":"Yang","year":"2022","journal-title":"Cancer Med"},{"key":"10.1016\/j.ijrobp.2023.05.021_bib0049","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1093\/jnci\/djp369","article-title":"Detecting an overall survival benefit that is derived from progression-free survival","volume":"101","author":"Broglio","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ijrobp.2023.05.021_bib0050","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1002\/cncr.11228","article-title":"Pattern of recurrence following complete resection of esophageal carcinoma and factors predictive of recurrent disease","volume":"97","author":"Mariette","year":"2003","journal-title":"Cancer"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301623004972?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301623004972?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T10:08:20Z","timestamp":1759745300000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301623004972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S0360301623004972"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2023.05.021","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Surrogate Endpoint for Overall Survival in Locally Advanced and Resectable Esophageal Squamous Cell Carcinoma: A Reanalysis of Data From the NEOCRTEC5010 Trial","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2023.05.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}